The US financial investor KKR is planning a billion-euro takeover of Biotage, which specializes in laboratory equipment and automation.
KKR is offering a price of 145 Swedish kronor per share via its subsidiary RWK BidCo AB - around 60% above the last closing price on April 17, 2025.
The total valuation is around 11.6 billion kronor (approx. 1.06 billion euros). Biotage generated sales of 2.06 billion kronor and earnings of 3.55 kronor per share in 2024 - this corresponds to a price/earnings ratio of just under 47.
The takeover is subject to KKR acquiring at least 90% of the shares and the approval of the relevant antitrust authorities.
In addition, the offer price could be reduced if a dividend of 1.65 kronor is approved at the Annual General Meeting on April 24.
More on private equity:
